沙利文发布《全球及中国合成生物与生物制造产业发展白皮书（2026）》
Frost & Sullivan Releases the " Global and China Biology and Bio-manufacturing Industry Development White Paper（2026）"
合成生物学是继DNA双螺旋结构、基因组技术之后的第三次生命科学革命，依托工程化、系统化的技术范式，重塑生物研发与生产逻辑，是全球生物经济与先进制造迭代升级的核心驱动力。合成生物学的技术突破，可通过生物制造的规模化生产实现最终产业价值，而生物制造想要真正突破技术转化的“死亡谷”，从实验室走向大规模产业化，可凭借合成生物学在菌种设计、代谢通路重构等环节的技术支撑实现。二者协同构建的产业体系，不仅重新定义了人类获取自然资源、加工制造产品的方式，更将重构全球产业格局、重塑国际竞争力逻辑，为各国实体经济发展创造全新的战略增长点。当前，全球主要经济体纷纷将合成生物与生物制造纳入未来产业的核心布局范畴，持续加码技术研发、创新平台搭建与产业化落地，推动技术成果加速渗透至生物医药、先进材料、消费品、农业、能源、环保等关键领域，使其成为全球科技竞争与产业博弈的核心高地。
在全球产业深度变革的大背景下，中国凭借坚定的顶层战略支持、坚实的产业基础、完善的制造体系、持续突破的科研实力以及规模庞大的终端需求场景，成为全球合成生物与生物制造产业不可或缺的重要增长极。究其原因，中国合成生物与生物制造领域于近年的技术迭代提速，核心菌种改造、代谢通路重构等关键技术持续突破；科研创新成果丰硕，高水平学术文献、核心专利产出规模稳居全球前列；同时中国中试平台、产业化基地加速布局，逐步补齐技术转化短板，构建起“基础研究 - 中试放大 - 产业落地”的完整发展链路。此外，中国政府高度重视合成生物与生物制造产业的发展，2025年的政府工作报告明确将生物制造列为五大未来产业之首，随后出炉的“十五五”规划纲要，更是进一步将生物制造作为培育新质生产力的核心支撑赛道，提出要推动生物制造尽快成为国民经济新的增长点 —— 这是国家基于全球产业演进规律、国内资源安全需求与绿色发展目标作出的顶层部署，为产业发展提供了明确的战略指引。
作为前沿科技与产业发展领域的权威全球增长咨询机构，弗若斯特沙利文基于对全球合成生物与生物制造产业的长期跟踪洞察、连续65年深耕全球产业市场的扎实研究积累，以及覆盖全球的产业数据与案例资源储备，延续2025年发布的《上海合成生物与生物制造产业发展白皮书（2025）》，于2026年初正式启动《全球及中国合成生物与生物制造产业发展白皮书（2026）》的筹建与编写工作。本白皮书的编写过程，完全遵循沙利文在产业研究领域的专业标准，依托“政 - 产 - 学 - 研 – 金 – 用 - 服”的协同研究框架，通过梳理全球多国产业政策、创新生态与集群发展模式，对标海内外头部企业、创新平台的发展路径，系统总结全球产业发展共性规律与区域差异化特征。同时结合中国产业科研优势、平台建设现状与产业化落地特点，深度挖掘产业资源禀赋、发展痛点与核心竞争优势，兼顾全球宏观格局与中国微观实践，确保研究视角全面、内容客观务实。
《全球及中国合成生物与生物制造产业发展白皮书（2026）》是一本兼具宏观战略视野与产业实践价值的权威专业报告，报告立足全球产业变革趋势，聚焦中国产业创新发展特色，系统梳理全球及中国产业发展现状、技术迭代趋势与未来发展路径，提炼适配行业发展的策略建议。本报告的核心目标是为政府机构、投资机构、产业界、科研机构及社会各界提供全面、客观、专业、可落地的行业发展启示与决策参考。
Synthetic biology represents the third revolution in life sciences, following the discovery of the DNA double helix and the advent of genomics technologies. Supported by an engineered and systematic technical paradigm, it reshapes the logic of biological research, development and production, and serves as a core driving force for the iterative upgrading of the global bioeconomy and advanced manufacturing. Technological breakthroughs in synthetic biology can deliver ultimate industrial value via scaled biomanufacturing. For biomanufacturing to truly cross the "valley of death" for technology translation and move from laboratories to large-scale industrialization, it can rely on technical support from synthetic biology in strain design, metabolic pathway reconstruction and other links. The industrial system built through the coordination of the two sectors not only redefines how humans obtain natural resources and manufacture products, but also restructures the global industrial landscape and recalibrates the logic of international competitiveness, creating new strategic growth drivers for the development of the real economy of all nations. At present, major global economies have incorporated synthetic biology and biomanufacturing into core layouts for future industries. They continue to increase investment in technological R&D, build innovation platforms and advance industrial application, accelerating the penetration of technological achievements into key sectors including biomedicine, advanced materials, consumer goods, agriculture, energy and environmental protection. This has made synthetic biology and biomanufacturing a central frontier for global technological competition and industrial rivalry.
Against the backdrop of profound global industrial transformation, China has evolved into an indispensable growth engine for the global synthetic biology and biomanufacturing industry, underpinned by robust top-level strategic support, solid industrial foundations, a complete manufacturing ecosystem, continuously advancing scientific research capabilities, and massive end-market demand scenarios. The rapid technological iteration in China’s synthetic biology and biomanufacturing sectors in recent years stems from sustained breakthroughs in core technologies such as strain engineering and metabolic pathway reconstruction. The sector boasts abundant scientific and innovative outputs, with China ranking among the world’s leaders in the volume of high-caliber academic publications and core patents. Meanwhile, China is accelerating the deployment of pilot-scale platforms and industrial bases, gradually bridging gaps in technology translation and forming a full development chain spanning "basic research – pilot scale-up – industrial implementation". Furthermore, the Chinese government attaches great importance to the development of synthetic biology and biomanufacturing. The 2025 Government Work Report designated biomanufacturing as the foremost of the five major future industries. Subsequently, the Outline of the 15th Five-Year Plan further identifies biomanufacturing as a core track for fostering new productive forces, and calls for efforts to turn biomanufacturing into a new growth pillar of the national economy at an early date. This top-level arrangement is formulated by the state in light of the evolution of global industries, domestic resource security needs and green development objectives, offering clear strategic guidance for industrial advancement.
As a globally authoritative growth consulting firm specializing in cutting-edge technology and industrial development, Frost & Sullivan leverages long-term tracking insights into the global synthetic biology and biomanufacturing industry, solid research experience spanning 65 years across worldwide industrial markets, and a repository of global industrial data and case studies. Building upon the Shanghai Synthetic Biology and Biomanufacturing Industry Development White Paper (2025) released in 2025, the firm officially initiated the compilation of the Global and China Biology and Bio-manufacturing Industry Development White Paper（2026）in early 2026. Compiled in strict accordance with Frost & Sullivan’s professional standards for industrial research, this white paper adopts a collaborative research framework covering "government, industry, academia, research, capital, end-users and service providers". It sorts out industrial policies, innovation ecosystems and cluster development models in multiple countries worldwide, benchmarks the development paths of leading enterprises and innovation platforms at home and abroad, and systematically summarizes universal laws governing global industrial development as well as regional differentiated characteristics. Combined with China’s strengths in industrial scientific research, status of platform construction and features of industrialization, the report conducts in-depth analysis of industrial resource endowments, development bottlenecks and core competitive advantages. Balancing the global macro landscape and micro-level industrial practices within China, it ensures comprehensive perspectives, objective analysis and pragmatic content.
Global and China Biology and Bio-manufacturing Industry Development White Paper（2026）is an authoritative professional report integrating macro strategic vision and practical industrial value. Rooted in trends of global industrial transformation and focused on distinctive innovation trajectories of China’s industry, the report systematically outlines the status quo, technological iteration trends and future development paths of the industry worldwide and in China, and puts forward actionable strategic recommendations for the sector. Its core objective is to provide government agencies, investment institutions, industrial players, research institutes and all stakeholders with comprehensive, objective, professional and implementable insights and decision-making references for industrial development.
点击以下链接，查看节选版 报告：
如果您对全球及中国合成生物与生物制造市场有进一步的研究需求，请联系我们：
沙利文 孙女士
E-mail: skyler.sun@frostchina.com
